News releases from AstraZeneca
CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia
January 25, 2021
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer
January 18, 2021
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or...
AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer
January 13, 2021
AstraZeneca will present new data from across the innovative lung cancer portfolio at the IASLC 2020 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of...
FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease
January 06, 2021
AstraZeneca’s FARXIGA (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type 2 diabetes (T2D).
ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer
December 21, 2020
AstraZeneca’s TAGRISSO® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung...
ENHERTU (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Durable Responses with New Data From DESTINY-Breast01 in HER2-positive Metastatic Breast Cancer
December 10, 2020
Updated results from the positive DESTINY-Breast01 Phase II trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to...
CORRECTING and REPLACING CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma
December 07, 2020
In the release that dated December 6, 2020, the "Summary of efficacy results" table should appear as follows:
CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia
December 07, 2020
A pooled analysis of cardiovascular (CV) safety data from 762 patients treated with CALQUENCE® (acalabrutinib) monotherapy for chronic lymphocytic leukemia (CLL), the most common type of adult...
AstraZeneca Demonstrates Growing Leadership in Breast Cancer at SABCS with Data From Its Innovative Medicines and Robust Pipeline
December 03, 2020
AstraZeneca will unveil new developments across a range of stages and subtypes of breast cancer at the 2020 San Antonio Breast Cancer Symposium (SABCS), which will be held virtually from 8 to 11...
AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small...
AstraZeneca will present new research aimed at addressing key unmet needs facing patients with blood cancers at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held...
Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA
November 13, 2020
New data from a large, contemporary US hospitalized heart failure (HF) registry confirms that four out of five (81.1%) patients with NYHA class II-IV HF with reduced ejection fraction (HFrEF), with and...
Tezepelumab NAVIGATOR Phase III Trial Met Primary Endpoint of a Statistically Significant and Clinically Meaningful Reduction in Exacerbations in a Broad Population of Patients With Severe Asthma
November 10, 2020
AstraZeneca and Amgen today announced positive results from the NAVIGATOR Phase III trial for the potential new medicine tezepelumab in patients with severe, uncontrolled asthma.
BRILINTA Approved in the US to Reduce the Risk of Stroke in Patients With an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
November 06, 2020
AstraZeneca’s BRILINTA® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National...
FASENRA® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial
October 29, 2020
High-level results from the PONENTE Phase IIIb open-label trial showed FASENRA® (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in OCS-dependent asthma patients with a broad...
ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer
October 28, 2020
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has received acceptance for its supplemental Biologics License Application (sBLA) and has...
FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With Chronic Kidney Disease Irrespective of Underlying Cause
October 23, 2020
A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s FARXIGA® (dapagliflozin), on top of standard of care, reduced the composite of worsening of kidney...
AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards
October 22, 2020
AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the second annual Cancer Community (C2) Awards. A part of the YOUR Cancer program, the C2 Awards...
TAGRISSO Granted Priority Review in the US for the Adjuvant Treatment of Patients With Early-stage EGFR-mutated Lung Cancer
October 20, 2020
AstraZeneca’s TAGRISSO® (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients...
AstraZeneca’s FARXIGA® (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the US for patients with chronic kidney disease (CKD), with and without type 2 diabetes (T2D).
LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
September 20, 2020
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a...
TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
September 19, 2020
Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a clinically meaningful improvement in central nervous...
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer With an Estimated 50% of Patients Surviving Four Years
September 18, 2020
Updated results from the PACIFIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS)...
LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo
September 18, 2020
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that LYNPARZA demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a...
Biopharma Leaders Unite to Stand With Science
September 08, 2020
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and...
Development of COVID-19 Vaccine AZD1222 Expands Into US Phase III Clinical Trial Across All Adult Age Groups
August 31, 2020
AZD1222 development expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity.1
FARXIGA Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in the Phase III DAPA-CKD Trial
August 30, 2020
Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s FARXIGA® (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal...
AstraZeneca today announced the first shipment of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2020-2021 influenza season. FLUMIST QUADRIVALENT, the only...
AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Same
August 11, 2020
AstraZeneca is partnering with Tony Hale, two-time Emmy-winning actor and author, to share his lifelong journey as an asthma sufferer, in an effort to help others understand the importance of learning...
TAGRISSO Granted Breakthrough Therapy Designation in the US for the Adjuvant Treatment of Patients With Stage IB-IIIA EGFR-mutated Lung Cancer
July 30, 2020
AstraZeneca’s TAGRISSO® (osimertinib) has been granted Breakthrough Therapy Designation (BTD) in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor...